For MC38, B16-F10, and LLC tumor models, 106 tumor cells were subcutaneously injected on the right flank of male mice. Tumor diameters were measured using calipers. Tumor volume was calculated. Anti-PD-L1 and IgG1 isotype antibodies were given intraperitoneally at a dose of 100 μg per mouse on day 3 after tumor cells inoculation, then every 3 days for the duration of the experiment.
For the vivo macrophage depletion experiments, wild type C57BL/6J mice or Batf3−/− mice were treated with anti-CSF1R as described previously (MacDonald et al., 2010 (link)). Mice were pre-treated with 800 μg anti-CSF1R (clone AFS98, BioXCell) or IgG control (clone 2A3, BioXCell) 4 days before tumor inoculation, followed with 400 μg anti-CSF1R or IgG control every 3 days sustained throughout tumor progression.
For the vivo macrophage depletion experiments, wild type C57BL/6J mice or Batf3−/− mice were treated with anti-CSF1R as described previously (MacDonald et al., 2010 (link)). Mice were pre-treated with 800 μg anti-CSF1R (clone AFS98, BioXCell) or IgG control (clone 2A3, BioXCell) 4 days before tumor inoculation, followed with 400 μg anti-CSF1R or IgG control every 3 days sustained throughout tumor progression.